Disease Control Priorities, Third Edition (Volume 3) Cancer

, by ; ; ;
Disease Control Priorities, Third Edition (Volume 3) Cancer by Gelband, Hellen; Jha, Prabhat; Sankaranarayanan, Rengaswamy; Horton, Susan, 9781464803499
Note: Supplemental materials are not guaranteed with Rental or Used book purchases.
  • ISBN: 9781464803499 | 1464803498
  • Cover: Paperback
  • Copyright: 11/9/2015

Purchase Options
  • Rent

    (Recommended)

    $28.84
    Term
    Due
    Price
    *This item is part of an exclusive publisher rental program and requires an additional convenience fee. This fee will be reflected in the shopping bag.
  • Buy New

    Usually Ships in 3-5 Business Days

    $36.92
Volume 3, Cancer, presents the complex patterns of cancer incidence and death around the world and evidence on effective and cost-effective ways to control cancers. The DCP3 evaluation of cancer will indicate where cancer treatment is ineffective and wasteful, and offer alternative cancer care packages that are cost-effective and suited to low-resource settings. Main messages from the volume include: -Quality matters in all aspects of cancer treatment and palliation. -Cancer registries that track incidence, mortality, and survival – paired with systems to capture causes of death are important to understanding the national cancer burden and the effect of interventions over time. -Effective interventions exist at a range of prices. Adopting 'resource appropriate' measures which allow the most effective treatment for the greatest number of people will be advantageous to countries. -Prioritizing resources toward early stage and curable cancers is likely to have the greatest health impact in low income settings. -Research prioritization is no longer just a global responsibility. Providing cancer treatment requires adequate numbers of trained healthcare professionals and infrastructure beyond what is available in most LMICs, especially low income countries. Careful patient monitoring is a requirement of good quality cancer care and this often involves laboratory tests in addition to clinical examination. Even if financing were immediately available to build or expand a cancer control system, reaching capacity will take many years.